MERCK PERFORMANCE MATERIALS LIMITED

1. Risk Rating: MEDIUM

The company is active, not insolvent, and its statutory filings are current. It is majority-owned by Merck group entities, suggesting institutional backing. However, the available data contains no balance sheet, profit and loss, or cash flow figures, and issued share capital is nominal at £1.00. Solvency and liquidity therefore cannot be verified from the evidence provided, creating information asymmetry for an investor.

2. Key Concerns

• No financial performance or position data: The company data set does not include fixed assets, current assets, current liabilities, net assets, or shareholders’ funds. Without the latest filed accounts, it is not possible to assess whether the company can meet its obligations or whether it holds sufficient working capital.
• Nominal share capital: Issued share capital is recorded as £1.00. This provides no tangible equity buffer and suggests the company may be reliant on group funding, retained earnings, or other undisclosed financing arrangements.
• Group-controlled governance structure: Multiple corporate entities act as directors and persons with significant control, including formation and secretarial service companies. This indicates a structured group vehicle rather than an independently managed operating business; the extent of operational autonomy and intercompany dependencies should be clarified.

3. Positive Indicators

• Active status and filing compliance: The company is active, not in liquidation or administration, and both its accounts and confirmation statement are up to date with no overdue filings.
• Majority group ownership: Merck Chemicals Ltd and Merck Life Science Uk Limited each hold more than 75% of shares and voting rights, with the right to appoint and remove directors. This affiliation may provide access to group resources and financial support.
• Established industrial classification: The company operates under SIC codes for the manufacture of inorganic basic chemicals and other chemical products, indicating activity in a defined manufacturing sector.

4. Due Diligence Notes

• Obtain the full annual accounts made up to 31 December 2025 to review fixed assets, current assets, current liabilities, net assets, shareholders’ funds, and any auditor’s opinion.
• Confirm whether the company trades independently or is dependent on intercompany funding, guarantees, or other support from Merck Chemicals Ltd or Merck Life Science Uk Limited.
• Review the confirmation statement for recent changes to share capital, persons with significant control, or director appointments.
• Clarify the current roles of the corporate directors (Inhoco Formations Limited and A G Secretarial Limited) and whether they remain active on the board.
• Verify that the registered address at Bedfont Lakes Business Park corresponds to an operational trading location rather than solely a service or correspondence address.
• Investigate the reason for the previous name change from AGHOCO 1898 Limited in January 2020 and whether any business or assets were transferred at that time.